Leinco Technologies

Anti-Human Cytokeratin 19 - Purified

Product Code:
 
LEI-C162
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
BA17
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Immunocytochemistry (ICC)
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This purified antibody is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C162-0.2mg0.2 mg£265.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
Anti-Cytokeratin 19 reacts strongly with luminal (secretory) epithelial cells but does not stain the basal (myoepithelial) cells. There is a subset of secretory epithelial cells which were Keratin 19- and are thought to be precursors to keratin 19+ cells.1,2
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Mammary organoids
Long Description:
Cytokeratin 19, a type I intermediate filament protein, it is the smallest known acidic cytokeratin. The degree of keratin 19 positivity in breast cancer distinguishes malignant from benign tumours.
Target:
Cytokeratin 19

References

1. Bartek J. et al. (1985) J. Cell Sci. 75:17 2. Bartek J. et al. (1985) Int. J. Cancer 36:299